Idelalisib: A Potent PI3K-Delta Inhibitor for Hematologic Malignancies and Beyond
Discover the targeted action of Idelalisib, a breakthrough in treating various blood cancers and inflammatory conditions.
Get a Quote & SampleProduct Core Value
![4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]](https://www.nbinno.com/2025/webimg/gemini_688eb249525db_1754182217.png)
Idelalisib
Idelalisib, also known as CAL-101 or GS-1101, is a highly selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta. This targeted approach is crucial as PI3K delta signaling is vital for the activation, proliferation, survival, and trafficking of B lymphocytes, which are often hyperactive in B-cell malignancies. By specifically inhibiting PI3K delta, Idelalisib exerts its therapeutic effect without compromising the PI3K signaling necessary for the normal function of healthy cells, distinguishing it from broader PI3K inhibitors that can lead to significant toxicities.
- Leverage the precision of Idelalisib PI3K delta inhibitor for advanced therapeutic applications.
- Explore the CAL-101 drug mechanism, designed for targeted intervention in specific cell types.
- Understand the potential of GS-1101 for lymphoma treatment and its role in cancer research.
- Investigate the benefits of PI3K delta targeting cancer therapy for improved patient outcomes.
Key Advantages Provided
Targeted Inhibition
Idelalisib offers precise inhibition of PI3K delta, a key player in B-cell malignancies, minimizing off-target effects and enhancing therapeutic specificity.
Oral Administration
As an orally available small molecule, Idelalisib provides a convenient and patient-friendly treatment option, simplifying administration compared to injectable therapies.
Clinical Validation
With FDA breakthrough therapy designation for relapsed chronic lymphocytic leukemia and ongoing idelalisib clinical trials, its efficacy is progressively validated for various hematologic cancers.
Key Applications
Hematologic Malignancies Treatment
Idelalisib is pivotal in treating conditions like refractory indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, offering new hope for patients with limited options.
Oncology Research
The drug serves as a critical tool for researchers studying the PI3K pathway and developing novel cancer therapies, aiding in understanding disease progression and resistance mechanisms.
Targeted Therapy Development
Its selective action makes it a prime candidate for combination therapies and further research into targeted therapy for various cancers where PI3K delta is implicated.
Inflammatory Conditions
Beyond cancer, research suggests Idelalisib may also have applications in managing inflammatory and autoimmune diseases due to PI3K delta's role in immune cell function.